EP1670817A2 - Uses of spatial configuration to modulate protein function - Google Patents
Uses of spatial configuration to modulate protein functionInfo
- Publication number
- EP1670817A2 EP1670817A2 EP04782529A EP04782529A EP1670817A2 EP 1670817 A2 EP1670817 A2 EP 1670817A2 EP 04782529 A EP04782529 A EP 04782529A EP 04782529 A EP04782529 A EP 04782529A EP 1670817 A2 EP1670817 A2 EP 1670817A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- protein
- function
- gene
- codon usage
- altered codon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
Definitions
- Changing the spatial configuration of proteins without disturbing amino acid sequence may change functions of certain proteins.
- some proteins with abnormal 3 -dimensional structure can cause diseases in humans and animals, such as: bovine spongiform encephalopathy (BSE), Alzheimer's Disease, cystic fibrosis, familial hypercholestrolacemia, familial amyloid disease, certain carcinoma or cataract. These diseases also have been called folding-drseases” .
- BSE bovine spongiform encephalopathy
- Alzheimer's Disease cystic fibrosis
- familial hypercholestrolacemia familial hypercholestrolacemia
- familial amyloid disease certain carcinoma or cataract.
- folding-drseases folding-drseases
- Samples contain 30 ⁇ g/ml IFN-conl, 5.9 mg/ml of NaCl and
- Samples contain 30 ⁇ g/ml rSIFN-co, 5.9 mg/ml of NaCl and
- This figure is the record of body temperature changes of 5 patients in Group A.
- FIG. 4A-2 Curves of Changes of Body Temperature in Group A (6 patients) This figure is the record of body temperature changes of the other 6 patients in Group A.
- This figure is the record of body temperature changes of 5 patients in Group B.
- This figure is the record of body temperature changes of the other 5 patients in Group B.
- This invention provides a set of methods for modulating protein spatial configuration.
- This invention provides a method for modulating the function of proteins without changing the primary amino acid sequence of said protein comprising steps of: a) altering the codon usage of said protein; b) expressing the protein using the altered codon to obtain purified protein; and c) comparing the expressed protein with altered codon usage to one without, wherein an increase in function or identification of new function indicates that the function of the protein has been modulated.
- the altered codon usage results in high expression of said protein.
- This invention also provides a method for preparing protein with enhanced or new functions without changing the primary amino acid sequence of said protein comprising steps of: a) altering the codon usage of said protein; b) expressing the protein using the altered codon to obtain purified protein; and c) comparing the expressed protein with altered codon usage to one without, wherein an increase in function or identification of new function indicates that a protein with enhanced and new function has been prepared.
- the altered codon usage results in high expression of said protein.
- This invention also provides the protein prepared by the above method.
- the protein has unique secondary or tertiary structure.
- This invention further provides a synthetic gene with altered codon, which, when expressed, produces enhanced or new functions.
- the invention provides a vector comprising the gene.
- this invention provides an expression system comprising the gene.
- this invention provides a host cell comprising the gene.
- This invention also provides a process for production of a protein of enhanced function or new function comprising introducing an artificial gene with selected codon preference into an appropriate host, culturing said introduced host under appropriate conditions for the expression of said protein, and harvesting the expressed protein.
- the process comprises extraction of the protein from fermentation broth, or collection of the inclusion body, and denaturation and renaturation of the harvested prucem.
- This invention also provides the protein produced by any of the above processes.
- This invention provides a composition comprising any of the above proteins and a suitable carrier.
- This invention further provides a pharmaceutical composition comprising any of the above produced proteins and a pharmaceutically acceptable carrier.
- One significance of this invention is that it modulates the spatial configuration of protein during the process of translating genes with therapeutic effects into proteins which possess functions originating from the genes, or functions not seen in proteins produced using traditional techniques, or even with improved activity compared with those existing proteins.
- rSIFN-co is a new interferon molecule constructed according to conservative amino acids in human IFN- ⁇ subtype with genetic engineering methods.
- the interferon has been described in United States Patent Nos. 4,695,263 and 4,897,471, and has been proven in literature and patents to have broad-spectrum interferon activity with strong antiviral, anti-tumor and natural cell-killing effects.
- the DNA coding sequence was redesigned according to E. Coli . codon usage by first constructing an insert into pHY- 4 vector, mediating down-stream expression with P B AD promoter, then choosing E. Coli. as host.
- the high-purity products are gained by denaturation with 6 mol/L guanidine hydrochloride ⁇ renatured with 4 mol/L arginine ⁇ purified with Cu 2+ -chelating affinity chromatography after POROS HS/M cation exchange chromatography.
- Solvent and Dispensing Method Add 1ml saline into each vial, dissolve, and mix with MEM culture medium at different concentrations. Mix on the spot.
- Control drugs IFN- ⁇ 2b (Intron A) as lyophilized powder, purchased from Schering Plough. 3xl0 6 U each, mix to 3xl0 6 IU/ml with culture medium; INFERGEN (liquid solution) , purchased from Amgen, 9 ⁇ g, 0.3ml each, equal to 9X10 6 IU, and mix with 9X10 6 IU/ml culture medium preserve at 4°C; 2.2.15 cell: 2.2.15 cell line of hepatoma (Hep G2) cloned and transfected by HBV DNA, constructed by Mount Sinai Medical Center.
- MEM powder Gibco American Ltd. cattle fetal blood serum, HycloneLab American Ltd. G-418 (Geneticin) ; MEM dispensing, Gibco American Ltd.; L-Glutamyl, imported and packaged by JING KE Chemical Ltd.; HBsAg and HBeAg solid- phase radioimmunoassay box, Northward Reagent Institute of
- 2.2.15 cell culture Add 0.25% pancreatic enzyme into culture box with full of 2.2.15 cell. Digest at 37°C for 3 minutes and add culture medium to stop digestion and disperse the cells. Reproduce with a ratio of 1:3. They will reach full growth in 10 days.
- Toxicity test Set groups of different concentrations and a control group in which cells are not acted on with medicine. Digest cells, and dispense to a 100,000 cell/ml solution. Inoculate to 96-well culture board, 200 ⁇ l per well. Culture at 37°C for 24h with 5% C0 2 . Test when simple cell layer grows.
- Dispense rSIFN-co to 1.8xl0 7 IU/ml solution then prepare a series of solutions diluted at two-fold gradients. Add into 96-well culture board, 3 wells per concentration. Change the solution every 4 days. Test cytopathic effect by microscope after 8 days. Fully destroy as 4, 75% as 3, 50% as 2, 25% as 1, zero as 0. Calculate average cell lesions and inhibition rates at different concentrations. Calculate TC50 and TC0 according to the Reed Muench method.
- TC50 Antilog (B + x C) A-B
- HBeAg and HBsAg Separate into positive and negative HBeAg and HBsAg contrast groups, cell contrast groups and medicine concentration groups. Inoculate 7 , 000 cells/ml of 2.2.15 cell into 6-well culture board, 3 ml per well, culture at 37°C for 24h with 5% C0 2 , then prepare 5 gradiently diluted solutions with 3- fold as the grade (Prepare 5 solutions, each with a different protein concentration.
- the concentration of Solution 2 is 3 times lower than that of Solution 1, the concentration of Solution 3 is 3 times lower than that of Solution 2, etc.) 4.5xl0 6 IU/ml , 1.5xl0 6 IU/ml , 0.5xl0 6 IU/ml, 0.17xl0 6 lU/ml, and 0.056xl0 6 lU/ml , 1 well per concentration, culture at 37°C for 24h with 5% C0 2 . Change solutions every 4 days using the same solution. Collect all culture medium on the 8 th day.
- Antigen inhibition rate (%) x 100
- Antigen inhibition IC50 Antilog (B + x C) A-B
- Southern blot (1) HBV-DNA extract in 2.2.15 cell: Culture cell 8 days. Exsuction culture medium (Separate cells from culture medium by means of draining the culture medium.). Add lysis buffer to break cells, then extract 2 times with a mixture of phenol, chloroform and isoamyl alcohol (1:1:1), 10,000g centrifuge. Collect the supernatant adding anhydrous alcohol to deposit nucleic acid. Vacuum draw, re- dissolve into 20 ⁇ lTE buffer. (2) Electrophoresis: Add 6XDNA loading buffer, electrophoresis on 1.5% agarose gel, IV/cm, at fixed pressure for 14-18h. (3) Denaturation and hybridization: respectively dip gel into HC1, denaturaion buffer and neutralization buffer. (4) Transmembrane : Make an orderly transfer of DNA to Hybond-N membrane. Bake, hybridize and expose with dot blot hybridization. Scan and analyze relative density with gel-pro software. Calculate inhibition rate and IC50.
- Results from Tables 1, 2 and 3 show: After maximum innocuous concentration exponent culturing for 8 days with 2.2.15 cell, the maxima is 9.0 + 0xl0 6 IU/ml average inhibition rate of maximum innocuous concentration rSIFN-co to HBeAg is 46.0 ⁇ 5.25% (P ⁇ OD001) , IC50 is 4.54 ⁇ 1.32X10 6 IU/ml, SI is 3.96; rate to HBsAg is 44.8+ 6.6%, IC50 is 6.49 ⁇ 0.42xl0 6 IU/ml, SI is 2.77. This shows that rSIFN-co can significantly inhibit the activity of HBeAg and HBsAg, but that the IFN of the contrast group and INFERGEN cannot.
- HBeAg Average IC50: 450.2434 SD: 132.315479
- HBsAg Average IC50: 649.1894 SD: 42.29580
- HBeAg Average IC50 : SD: HBsAg : Average IC50 : SD:
- Hepatitis B virus (HBV) DNA contains consensus elements for transactivating proteins whose binding activity is regulated by interferons.
- Treatment of HBV-infected hepatocytes with interferons leads to inhibition of HBV gene expression.
- the aim of the present study was to characterize the effects of different interferons on HBV regulated transcription.
- Using transient transfection of human hepatoma cells with reporter plasmids containing the firefly luciferase gene under the control of HBV-Enhancer (EnH) I, Enh II and core promoter Applicant studied the biological activities of three different interferons on transcription .
- Interferons IFN-conl (Jnfergen ) , IFN-Hui-Yang ( ⁇ SIFN- co) and IFN-beta lb
- Reporter plasmid The DNA fragments containing HBV- Enhancer (EnH) I, Enh II and core promoter were prepared using PCR and blunt-end cloned into the Smal I site of the promoter- and enhancer-less firefly luciferase reporter plasmid pGL3-Basic (Promega, WI , USA). The resulting reporter plasmid was named as pGL3-HBV-Luc .
- HepG2 cells were cultured in DME medium supplemented with 10% FBS and 100 U/ml penicillin and 100 ug/ml streptomycin. The cells were kept in 30°C, 5% C02 incubator. The cells were transfected with pGL3-HBV-Luc reporter plasmid using Boehringer's Lipofectin transfection kit. After 18 hours, the medium containing transfection reagents was removed and fresh medium was added with or without interferons . The cells were kept in culture for another 48 hours.
- Luciferase Assay Forty-eight hours after the addition of interferon, the cells were harvested and cell lysis were prepared. The protein concentration of cell lysates were measured using Bio-Rad Protein Assay kit. The luciferase activity was measured using Promega's Luciferase Reporter Assay Systems according to the instructions of manufacturer.
- the side effects include: nausea, muscle soreness, loss of appetite, hair loss, hypoleucocytosis (hypoleukmia; hypoleukocytosis; hypoleukia) , and decrease in blood platelets, etc.
- Group A were injected with 9 ⁇ g Infergen 3 . 10 patients in
- Group B were injected with 9 ⁇ g ⁇ SIFN-co. Both groups were monitored for 48 hours after injections. First monitoring was recorded 1 hour after injection, after that, records were taken every 2 hours .
- Table 4 is the comparison of side effects between patients being injected with 9 ⁇ g of Infergen and 9 ⁇ g of ⁇ SIFN-co.
Abstract
Description
Claims
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49844903P | 2003-08-28 | 2003-08-28 | |
US49892303P | 2003-08-28 | 2003-08-28 | |
US49878503P | 2003-08-28 | 2003-08-28 | |
IN280MU2004 | 2004-03-05 | ||
IN279MU2004 | 2004-03-05 | ||
PCT/US2004/028068 WO2005021777A2 (en) | 2003-08-28 | 2004-08-26 | Uses of spatial configuration to modulate protein function |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1670817A2 true EP1670817A2 (en) | 2006-06-21 |
EP1670817A4 EP1670817A4 (en) | 2008-07-16 |
Family
ID=34280101
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04809634.1A Active EP1663110B1 (en) | 2003-08-28 | 2004-08-26 | Uses of interferons with altered spatial structure |
EP04782529A Ceased EP1670817A4 (en) | 2003-08-28 | 2004-08-26 | Uses of spatial configuration to modulate protein function |
EP10193126.9A Active EP2325202B1 (en) | 2003-08-28 | 2004-08-26 | Uses of interferons with altered spatial structure |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04809634.1A Active EP1663110B1 (en) | 2003-08-28 | 2004-08-26 | Uses of interferons with altered spatial structure |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10193126.9A Active EP2325202B1 (en) | 2003-08-28 | 2004-08-26 | Uses of interferons with altered spatial structure |
Country Status (8)
Country | Link |
---|---|
EP (3) | EP1663110B1 (en) |
JP (4) | JP5663768B2 (en) |
KR (2) | KR20060130009A (en) |
AU (2) | AU2004279350B2 (en) |
CA (2) | CA2535902A1 (en) |
HK (2) | HK1091756A1 (en) |
PL (2) | PL2325202T3 (en) |
WO (2) | WO2005021777A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8551469B2 (en) | 2001-02-28 | 2013-10-08 | Superlab Far East Limited | Treatment of tumors and viral diseases with recombinant interferon alpha |
CN1245215C (en) | 2001-02-28 | 2006-03-15 | 四川省生物工程研究中心 | Recombination high efficiency composite interferon used as hepatitis B surface antigen and e antigen inhibitor |
US7585647B2 (en) | 2003-08-28 | 2009-09-08 | Guangwen Wei | Nucleic acid encoding recombinant interferon |
EP1663110B1 (en) * | 2003-08-28 | 2013-12-18 | Superlab Far East Limited | Uses of interferons with altered spatial structure |
WO2006076014A2 (en) * | 2004-04-30 | 2006-07-20 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Interferon-alpha constructs for use in the treatment of sars |
US20080124302A1 (en) | 2005-03-09 | 2008-05-29 | Guangwen Wei | Uses of Recombinant Super-Compound Interferons |
CN102101886A (en) * | 2009-12-18 | 2011-06-22 | 四川辉阳生命工程股份有限公司 | Variable-conformation recombinant interferon crystal, and three-dimensional structure and use thereof |
TW201427681A (en) * | 2013-01-07 | 2014-07-16 | Superlab Far East Ltd | A method for treating tumor by using recombinant interferon with changed spatial configuration |
CN111363726A (en) | 2018-12-26 | 2020-07-03 | 上海元宋生物技术有限公司 | Oncolytic virus expressing interferon and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002080958A1 (en) * | 2001-02-28 | 2002-10-17 | Sichuan Biotechnology Research Center | Recombination super compound interferon used as hepatitis b surface antigen and e antigen inhibitor |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6936694B1 (en) * | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
US5372808A (en) | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
ATE328069T1 (en) * | 1995-10-13 | 2006-06-15 | Harvard College | PHOSPHOPANTETHENYL TRANSFERASES AND USES THEREOF |
US5874304A (en) * | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
US20020043262A1 (en) * | 2000-08-22 | 2002-04-18 | Alan Langford | Spray device |
EP1355939A2 (en) * | 2000-11-03 | 2003-10-29 | Pestka Biomedical Laboratories, Inc. | Interferons, uses and compositions related thereto |
EP1663110B1 (en) * | 2003-08-28 | 2013-12-18 | Superlab Far East Limited | Uses of interferons with altered spatial structure |
-
2004
- 2004-08-26 EP EP04809634.1A patent/EP1663110B1/en active Active
- 2004-08-26 KR KR1020067003699A patent/KR20060130009A/en not_active Application Discontinuation
- 2004-08-26 WO PCT/US2004/028068 patent/WO2005021777A2/en active Search and Examination
- 2004-08-26 PL PL10193126T patent/PL2325202T3/en unknown
- 2004-08-26 JP JP2006524916A patent/JP5663768B2/en active Active
- 2004-08-26 EP EP04782529A patent/EP1670817A4/en not_active Ceased
- 2004-08-26 KR KR1020067003700A patent/KR20060133949A/en not_active Application Discontinuation
- 2004-08-26 JP JP2006524917A patent/JP2007503812A/en active Pending
- 2004-08-26 WO PCT/US2004/028067 patent/WO2005034853A2/en active Application Filing
- 2004-08-26 AU AU2004279350A patent/AU2004279350B2/en active Active
- 2004-08-26 AU AU2004269390A patent/AU2004269390A1/en not_active Abandoned
- 2004-08-26 CA CA002535902A patent/CA2535902A1/en not_active Abandoned
- 2004-08-26 EP EP10193126.9A patent/EP2325202B1/en active Active
- 2004-08-26 PL PL04809634T patent/PL1663110T3/en unknown
- 2004-08-26 CA CA2535982A patent/CA2535982C/en active Active
-
2006
- 2006-12-07 HK HK06113460.8A patent/HK1091756A1/en unknown
-
2011
- 2011-01-21 JP JP2011011325A patent/JP2011083292A/en active Pending
- 2011-11-25 HK HK11112807.5A patent/HK1158231A1/en unknown
-
2012
- 2012-05-28 JP JP2012121307A patent/JP5709800B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002080958A1 (en) * | 2001-02-28 | 2002-10-17 | Sichuan Biotechnology Research Center | Recombination super compound interferon used as hepatitis b surface antigen and e antigen inhibitor |
Non-Patent Citations (3)
Title |
---|
AMATO I: "Silent no longer", CHEMICAL AND ENGINEERING NEWS, vol. 85, no. 4, 22 January 2007 (2007-01-22), pages 38-40, * |
Anonymous: "Infergen", , 30 November 1998 (1998-11-30), * |
See also references of WO2005021777A2 * |
Also Published As
Publication number | Publication date |
---|---|
AU2004279350A1 (en) | 2005-04-21 |
KR20060133949A (en) | 2006-12-27 |
CA2535902A1 (en) | 2005-03-10 |
EP1663110B1 (en) | 2013-12-18 |
JP5663768B2 (en) | 2015-02-04 |
AU2004279350B2 (en) | 2011-03-10 |
WO2005034853A3 (en) | 2006-04-27 |
JP2011083292A (en) | 2011-04-28 |
HK1091756A1 (en) | 2007-01-26 |
EP1663110A4 (en) | 2008-07-16 |
WO2005034853A2 (en) | 2005-04-21 |
CA2535982A1 (en) | 2005-04-21 |
AU2004269390A1 (en) | 2005-03-10 |
WO2005021777A3 (en) | 2005-05-12 |
KR20060130009A (en) | 2006-12-18 |
PL2325202T3 (en) | 2015-03-31 |
EP1670817A4 (en) | 2008-07-16 |
CA2535982C (en) | 2016-11-29 |
WO2005021777A2 (en) | 2005-03-10 |
JP5709800B2 (en) | 2015-04-30 |
EP2325202B1 (en) | 2014-10-22 |
JP2007516214A (en) | 2007-06-21 |
EP2325202A1 (en) | 2011-05-25 |
PL1663110T3 (en) | 2014-07-31 |
JP2012162567A (en) | 2012-08-30 |
EP1663110A2 (en) | 2006-06-07 |
HK1158231A1 (en) | 2012-09-14 |
JP2007503812A (en) | 2007-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8425896B2 (en) | Treatment of tumors with recombinant interferon alpha | |
JP2011083292A (en) | Modulation of protein function by spatial configuration | |
JPH11511324A (en) | How to increase interferon production in cell culture | |
TWI720268B (en) | Method for preparing electrocompetent yeast cells, and method for using said cells | |
JPH0948799A (en) | Interferon of animal | |
US8287852B2 (en) | Treatment of viral diseases with recombinant interferon α | |
US20150174206A1 (en) | Uses of interferons with altered spatial structure | |
Zhou et al. | Production of hepatitis B virus nucleocapsidlike core particles in Xenopus oocytes: assembly occurs mainly in the cytoplasm and does not require the nucleus | |
US20110070195A1 (en) | Uses of spatial configuration to modulate protein function | |
US20060035327A1 (en) | Recombinant super-compound interferon and uses thereof | |
CN101747437A (en) | Apoptin-EC-SOD carboxyl terminal protein transduction domain fusion protein | |
Thornton et al. | Microinjection of vesicular stomatitis virus ribonucleoprotein into animal cells yields infectious virus | |
Maroun et al. | Increased messenger RNA from protein synthesis inhibited human fibroblasts | |
CN113943359A (en) | Calcium binding protein ASP-3 with antitumor activity and derived from Arca subcrenata and structure thereof | |
US20090123417A1 (en) | Recombinant super-compound interferon and uses thereof | |
CN116479046A (en) | Use of DOCK8 gene in regulation of HTLV-1 virus infection | |
CN117645996A (en) | Nucleic acid 5' UTR molecules and uses thereof | |
CN117660526A (en) | SARS-CoV-2 immunogen and its application | |
CN115894658A (en) | Long-chain non-coding RNA ZFAS1 coded micro-peptide and application thereof | |
Carey | Production and use of therapeutic agents. | |
Krippl et al. | Functional Domains of Purified Adenovirus Type C E1A Proteins | |
JPH11513891A (en) | Cell line | |
KR20000076670A (en) | Growth hormone-regulated growth marker |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20060324 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1091846 Country of ref document: HK |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20080617 |
|
17Q | First examination report despatched |
Effective date: 20081127 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R003 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20110628 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1091846 Country of ref document: HK |